340B hospitals linked to higher assets and admin salaries

A new Health Affairs Scholar study finds long-term participation in the federal 340B Drug Pricing Program is associated with stronger hospital balance sheets and higher administrative spending. The findings add fresh scrutiny to a program that has grown to more than $80 billion in discounted drug purchases and is under debate over whether its benefits reach vulnerable patients.

Why it matters: - The study suggests the 340B Drug Pricing Program may be boosting hospital finances more than patient care for low-income communities. - Researchers found the biggest gains were concentrated at participating hospitals and their child sites, raising questions about where 340B savings go. - The findings add to calls for more transparency around 340B proceeds and how hospitals use them.

What happened: - New research in the peer-reviewed Health Affairs Scholar found that 340B-participating hospitals had 47.5 percent higher total assets than structurally similar non-340B hospitals after controlling for size, teaching status, revenue and profitability. - The study, titled “Association of 340B Entity Eligibility With Changes in Hospital Financial Performance,” was conducted by the National Pharmaceutical Council and Health Capital Group. - Neal Masia, Jon Campbell, Yevgeniy Feyman and Kenneth Finegold authored the paper. - The analysis covered 2,605 community hospitals from 2013 to 2023 using Medicare Cost Report data and HRSA’s Office of Pharmacy Affairs Information System.

The details: - Long-term 340B participation was associated with faster asset growth over a decade, rather than just a one-time financial snapshot. - The average large 340B hospital was associated with roughly $276 million in additional assets. - Across the 1,029 large 340B hospitals studied, the authors estimate $284 billion in 340B assets as of 2023. - Participation was associated with 22.8 percent higher administrative salary spending, or about $7 million more per year. - Hospitals operating more sites posted faster asset growth. - Much of the recent growth flowed through child sites, outpatient clinics that operate under a parent hospital’s 340B eligibility but are not required to serve the same low-income patients. - HRSA says the 340B program accounted for more than $80 billion in discounted drug purchases by covered entities in 2024. - A 2025 majority staff report from the U.S. Senate HELP Committee found that two large 340B health systems generated hundreds of millions in savings and revenue between 2018 and 2023. - A Minnesota Department of Health report found the largest 340B hospitals captured more than 80 percent of statewide revenue, over $1 billion. - The Congressional Budget Office said last year that the 340B program increases federal spending.

Between the lines: - The study strengthens the argument that 340B participation is linked to financial accumulation at large nonprofit hospitals. - The pattern may support critics who say the program has drifted from its original goal of helping vulnerable patients afford medicines. - The heavy use of child sites suggests the program’s benefits may extend beyond the settings most tied to low-income care. - The findings do not prove how hospitals use 340B revenue, but they sharpen the pressure for reporting on spending and outcomes.

What's next: - The authors say more research is needed on how hospitals use 340B proceeds. - Greater transparency around program revenue and spending is likely to remain a policy focus as scrutiny of hospital finances continues. - The debate over whether 340B growth benefits patients, hospitals or taxpayers is likely to intensify.

The bottom line: - Long-term 340B participation appears tied to stronger hospital balance sheets and higher administrative costs, not just more access to discounted drugs.